BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 508562)

  • 1. Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.
    Workman P
    Br J Cancer; 1979 Sep; 40(3):335-53. PubMed ID: 508562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.
    Brown JM; Yu NY; Workman P
    Br J Cancer; 1979 Mar; 39(3):310-20. PubMed ID: 465300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.
    Workman P
    Cancer Chemother Pharmacol; 1980; 5(1):27-37. PubMed ID: 7460192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hepatic microsomal enzyme inducers on the metabolism of misonidazole in rats.
    Shoemaker D; Upton D; Strong J
    Cancer Treat Rep; 1980; 64(2-3):275-7. PubMed ID: 7407761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of phenytoin, phenobarbital, and ascorbic acid on misonidazole elimination.
    Williams K; Begg E; Wade D; O'Shea K
    Clin Pharmacol Ther; 1983 Mar; 33(3):314-21. PubMed ID: 6825387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of phenytoin, phenobarbitone, dexamethasone and flurbiprofen on misonidazole neurotoxicity in mice.
    Sheldon PW; Clarke C; Dawson KB
    Br J Cancer; 1984 Feb; 49(2):207-13. PubMed ID: 6696821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution and tumour cytotoxicity of the radiosensitizer misonidazole (Ro-07-0582) in C57 mice.
    Pedersen JE; Smith MR; Bugden RD; Peckham MJ
    Br J Cancer; 1979 Apr; 39(4):429-33. PubMed ID: 444398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The penetration of misonidazole into spontaneous canine tumours.
    White RA; Workman P; Owen LN; Bleehen NM
    Br J Cancer; 1979 Aug; 40(2):284-94. PubMed ID: 289406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetized mouse.
    Honess DJ; Workman P; Morgan JE; Bleehen NM
    Br J Cancer; 1980 Apr; 41(4):529-40. PubMed ID: 7387851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice.
    Walton MI; Bleehen NM; Workman P
    Br J Cancer; 1987 May; 55(5):469-76. PubMed ID: 3606940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of dexamethasone in the modification of misonidazole pharmacokinetics.
    Jones DH; Bleehen NM; Workman P; Walton MI
    Br J Cancer; 1983 Oct; 48(4):553-7. PubMed ID: 6626454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug interactions with misonidazole: effects of dexamethasone and its derivatives on the pharmacokinetics and toxicity of misonidazole in mice.
    Workman P
    Biochem Pharmacol; 1980 Oct; 29(20):2769-76. PubMed ID: 7437082
    [No Abstract]   [Full Text] [Related]  

  • 13. Phenytoin sodium-induced alterations in the pharmacokinetics of misonidazole in the dog.
    White RA; Workman P
    Cancer Treat Rep; 1980; 64(2-3):360-1. PubMed ID: 7190871
    [No Abstract]   [Full Text] [Related]  

  • 14. Kinetics of misonidazole enantiomers.
    Williams KM
    Clin Pharmacol Ther; 1984 Dec; 36(6):817-23. PubMed ID: 6499361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasma and tissues distribution of misonidazole (RO 07-0582) in the rat bearing a chimio induced tumor (author's transl)].
    Akel G; Canal P; Bugat R; Soula G; Combes PF
    J Pharmacol; 1981; 12(4):383-91. PubMed ID: 7321570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.
    Lee FY; Workman P
    Br J Cancer; 1983 May; 47(5):659-69. PubMed ID: 6849803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.
    White RA; Workman P
    Br J Cancer; 1980 Feb; 41(2):268-76. PubMed ID: 7370166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
    Akel G; Canal P; Mockey E; Vandevoorde E; Laurent F; Soula G
    J Pharmacol; 1983; 14(1):67-77. PubMed ID: 6834852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desmethylmisonidazole (Ro 05-9963): clinical pharmacokinetics after multiple oral administration.
    Stratford MR; Minchinton AI; Dische S; Saunders MI; Anderson P
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):377-9. PubMed ID: 7107355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole.
    White R; Workman P; Owen L
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):473-6. PubMed ID: 7107369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.